EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Performance of Bleeding Risk Scores for Major Bleeding in Anticoagulated Patients with Pulmonary Embolism: Insights from the CURES Registry-2

Yuzhi Tao, Hong Chen, Chunling Dong, Jie Zhang, Yiwei Shi, Xiaomao Xu, Maoyun Wang, Ling Zhu, Juhong Shi, Yingqun Ji, Hong Chen, Zhe Cheng und 24 weitere

Thrombosis and Haemostasis · 01.05.2026 · 126 (05) · 496-508

DOI: 10.1055/a-2642-0241 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.05.2026. Verfasst von Yuzhi Tao und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The First Bethune Hospital of Jilin University, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Pulmonary Embolism, Hemorrhage, Anticoagulants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the CAMS Innovation Fund for Medical Sciences (CIFMS), National High Level Hospital Clinical Research Funding, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most bleeding risk scores for pulmonary embolism (PE) were developed in patients receiving traditional anticoagulants. Evidence in East Asian populations and its applicability to direct oral anticoagulants (DOACs) remain limited. This post-hoc analysis was based on a multicentre, prospective study (NCT02943343) conducted from 2016 to 2021. The predictive performance of bleeding risk scores was assessed using a time-dependent area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), and decision curve analysis (DCA). Propensity score matching (PSM) was adjusted for baseline characteristics. We analyzed the impact of initial DOAC versus low-molecular-weight heparin (LMWH) on outcomes. The endpoint was major bleeding (MB) within 90 days and composite outcomes (all-cause mortality, recurrent VTE, and MB). Of 7,619 patients with PE, 1.4% (107 patients) experienced MB within 90 days. The RIETE score showed a modest predictive ability (AUC: 0.70; 95% CI, 0.65–0.75) for predicting 90-day MB and demonstrated a predictive advantage in the DCA results. NRI also revealed significantly better reclassification capability than the other scores, except for HAS-BLED. Among low-risk patients classified by the RIETE score, initial DOAC treatment significantly reduced 14-day composite outcomes compared with LMWH (HR = 0.13; 95% CI, 0.02–0.93). Furthermore, DOACs at discharge did not increase the risk of MB or composite outcomes. RIETE score shows modest performance in predicting MB and identifying low bleeding risk in PE patients, which could potentially guide early DOAC use. Further studies are needed to test its clinical utility, especially in East Asian populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmbolismHemorrhageAnticoagulantsHumansMaleFemaleAgedMiddle AgedProspective StudiesRisk AssessmentRegistriesRisk FactorsHeparin, Low-Molecular-WeightFactor Xa InhibitorsAdministration, OralAged, 80 and overPropensity ScoreTreatment OutcomeRecurrence

Substanzen

AnticoagulantsHeparin, Low-Molecular-WeightFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, The First Bethune Hospital of Jilin University, Jilin University, Changchun, China.
  • National Centre for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Centre for Respiratory Diseases, Beijing, China.
  • Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.
  • Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Pulmonary and Critical Care Medicine, The Second Hospital, Jilin University, Changchun, China.

Förderung

  • the CAMS Innovation Fund for Medical Sciences (CIFMS)
  • National High Level Hospital Clinical Research Funding
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Ministry of Science and Technology of the People's Republic of China

Zitieren

APA

Tao, Y., Chen, H., Dong, C., Zhang, J., Shi, Y., Xu, X., Wang, M., Zhu, L., Shi, J., Ji, Y., Chen, H., Cheng, Z., Tang, Y., Li, Y., Deng, C., Luo, Q., Lu, P., Yang, Y., Xi, L., …, & CURES investigators (2026). Performance of Bleeding Risk Scores for Major Bleeding in Anticoagulated Patients with Pulmonary Embolism: Insights from the CURES Registry-2. Thrombosis and Haemostasis, 126(05), 496-508. https://doi.org/10.1055/a-2642-0241

Vancouver

Tao Y, Chen H, Dong C, Zhang J, Shi Y, Xu X, et al. Performance of Bleeding Risk Scores for Major Bleeding in Anticoagulated Patients with Pulmonary Embolism: Insights from the CURES Registry-2. Thrombosis and Haemostasis. 2026;126(05):496-508. doi:10.1055/a-2642-0241

BibTeX
@article{Tao2026,
  author = {Tao, Yuzhi and Chen, Hong and Dong, Chunling and Zhang, Jie and Shi, Yiwei and Xu, Xiaomao and Wang, Maoyun and Zhu, Ling and Shi, Juhong and Ji, Yingqun and Chen, Hong and Cheng, Zhe and Tang, Yongjun and Li, Yanxia and Deng, Chaosheng and Luo, Qin and Lu, Pinyao and Yang, Yuanhua and Xi, Linfeng and Zhang, Yu and Liang, Rui and Wang, Dingyi and Fan, Guohui and Xie, Wanmu and Wan, Jun and Zhang, Zhu and Zhang, Shuai and Zhang, Yunxia and Huang, Qiang and Gao, Qian and Liu, Min and Yang, Peiran and Wang, Shengfeng and Wang, Chen and Zhai, Zhenguo and CURES investigators, CURES investigators},
  title = {Performance of Bleeding Risk Scores for Major Bleeding in Anticoagulated Patients with Pulmonary Embolism: Insights from the CURES Registry-2},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {05},
  pages = {496--508},
  doi = {10.1055/a-2642-0241}
}
Kostenlos starten →